RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance
[EN] Background. We recently conducted a phase 2 trial (NCT028865685) evaluating intracranial efficacy of
pembrolizumab for brain metastases (BM) of diverse histologies. Our study met its primary efficacy endpoint and
illustrates that pembrolizumab exerts promising activity in a select group of patients with BM. Given the importance of aberrant vasculature in mediating immunosuppression, we explored the relationship between immune
checkpoint inhibitor (ICI) efficacy and vascular architecture in the hopes of identifying potential mechanisms of
intracranial ICI response or resistance for BM.
Methods. Using Vessel Architectural Imaging, a histologically validated quantitative metric for in vivo tumor vascular physiology, we analyzed dual-echo DSC/DCE MRI for 44 patients on trial. Tumor and peri-tumor cerebral
blood volume/flow, vessel size, arterial and venous dominance, and vascular permeability were measured before
and after treatment with pembrolizumab.
Results. BM that progressed on ICI were characterized by a highly aberrant vasculature dominated by largecaliber vessels. In contrast, ICI-responsive BM possessed a more structurally balanced vasculature consisting of
both small and large vessels, and there was a trend toward a decrease in under-perfused tissue, suggesting a
reversal of the negative effects of hypoxia. In the peri-tumor region, the development of smaller blood vessels,
consistent with neo-angiogenesis, was associated with tumor growth before radiographic evidence of contrast
enhancement on anatomical MRI.
Conclusions. This study, one of the largest functional imaging studies for BM, suggests that vascular architecture
is linked with ICI efficacy. Studies identifying modulators of vascular architecture, and effects on immune activity,
are warranted and may inform future combination treatments., A.E.K. is supported by an American Brain Tumor Association Basic Research Fellowship In Honor of Paul Fabbri, the William
G. Kaelin, Jr., MD, Physician-Scientist Award of the Damon Runyon Cancer Research Foundation, American Association for Cancer Research Breast Cancer Research Fellowship, and American Society of Clinical Oncology Young Investigator Award. E.F.G. was supported by the European Union s Horizon 2020 Programme: Marie Sklodowska-Curie grant agreement No 844646-GLIOHAB and Spanish State Research
Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00). P.K.B is supported by the NCI
(1R01CA227156-01, 5R21CA220253-02, and 1R01CA244975-01), Damon Runyon Cancer Research Foundation, and Breast
Cancer Research Foundation. Y.Y. is supported by the NIH (1R21AG067562-01 and 1R21GM137227-01). K.E.E. is supported
by the European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, South-Eastern Norway Regional Health Authority (Grant Agreements No. 2016102, 2017073, 2013069), and the Norwegian Cancer Society and the FRIPRO Grant Agreements No. 261984, 303249). E.R.G. is supported by R01CA211238-01 and R01CA244975.
Project:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-127110OA-I00
,
Norges forskningsråd / H2020 261984
,
European Commission / MSCA-IF-EF-ST 758657
,
National Cancer Institute 5R21CA220253-02
,
EEUU 1R01CA244975-01
,
National Cancer Institute 1R01CA227156-01
,
EEUU 1R21GM137227-01
,
National Cancer Institute 1R21AG067562-01
,
EEUU 2017073
,
National Institutes of Health 2013069
,
EEUU 2016102
,
National Institutes of Health 844646
,
EEUU 303249